The self-expanding valve is not yet approved by the FDA, but care teams in other markets are reporting positive outcomes when patients go home the day after treatment. 

Patients with pulmonary hypertension are associated with increased short- and long-term risks of death following TAVR. Researchers emphasized the importance of learning as much as possible about this topic going forward. 

As one may expect, advances in TAVR and TMVR technologies are seen as key drivers of the market’s success.

Each valve type has its own benefits, researchers noted, but mechanical valves are associated with multiple long-term benefits compared to tissue/bioprosthetic valves. 

Persistent and paroxysmal atrial fibrillation appear to affect short- and long-term TAVR mortality rates in different ways, according to a new study of nearly 3,000 patients. Some trends fade over time, while others remain in place after many years. 

It's clear that advanced AI algorithms will radically transform care for TAVR patients in the years ahead. For now, however, certain AI models may require too much data to be helpful on a consistent basis. 

Delaying TAVR in eligible patients with severe AS can lead to much higher healthcare costs, according to a new study of real-world Medicare data.

While multiple studies have confirmed that TAVR and surgery are associated with comparable outcomes, it is important to take an individualized approach to all treatment decisions.